FIGHT-RP 1 Extension Study

Key facts

Sponsor

Johns Hopkins University

Principal Investigator

Peter Campochiaro

Johns Hopkins University

Intervention

NAC effervescent tablets(drug)

Enrollment

30 enrolled

Eligibility

18 years · All sexes

Timeline

2019 – 2027

Study locations (1)

• Wilmer Eye Institute at Johns Hopkins University, Baltimore, Maryland, United States

Collaborators

Zambon SpA

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for OBSOLETE: Inherited retinal disorder

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT07408232
  A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)
  Octant, Inc.
• RECRUITINGEARLY PHASE1NCT07063030
  A Study of LX107 Gene Therapy in AIPL1-IRD Patients
  Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
• RECRUITINGPHASE1, PHASE2NCT06852963
  A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
  PYC Therapeutics
• RECRUITINGPHASE1NCT06319872
  The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
  University of Rochester
• RECRUITINGPHASE1NCT06936787
  An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa
  Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
• ENROLLING BY INVITATIONNCT07056738
  Prospective Exploratory Cohort Study on Ganglion Cell Degeneration in Retinitis Pigmentosa Patients
  University Medical Center Goettingen
• ACTIVE NOT RECRUITINGPHASE3NCT06388200
  A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
  Ocugen
• RECRUITINGPHASE1NCT06455826
  MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)
  PYC Therapeutics

See all trials for OBSOLETE: Inherited retinal disorder →